D2 Solutions, a healthcare consulting and technology company focused on market access, reimbursement, and patient support, announced it has acquired ProModRx, a cloud-based technology platform designed to accelerate patient access to prescription medications.
The acquisition enhances D2 Solutions’ ability to support pharmaceutical and medical device manufacturers, as well as traditional hubs and pharmacies, across the full patient journey. This includes therapy initiation, prescription capture, electronic benefits verification, prior authorization support, dispensing coordination, and ongoing patient engagement.
The expanded platform comes at a time when patient access challenges remain significant. According to D2 research, 21% of adults delayed starting prescribed medications due to confusion or access barriers. Additionally, 11% did not pick up prescriptions, 12% skipped doses, and 8% discontinued treatment earlier than planned.
The deal also reflects increasing pressure across the healthcare ecosystem, where patients, providers, and manufacturers must navigate complex reimbursement structures and evolving pricing and policy dynamics.
Through the acquisition, D2 strengthens its UltraTouch Verify and UltraTouch Engage offerings. UltraTouch Verify is designed to reduce therapy delays through electronic benefit verification, comprehensive coverage insights, prior authorization workflows, prescriber-input collection, and automated appeals processes. UltraTouch Engage focuses on earlier and more consistent patient interaction through automated outreach, enrollment and onboarding support, and multilingual digital communication.
The combined capabilities extend D2’s reach across retail, hospital, mail-order, and specialty pharmacy channels, while reinforcing its support for reimbursement, enrollment, and product access coordination.
As part of the transaction, ProModRx employees will remain with the business, and ProModRx General Manager Jerry Smith will join D2 Solutions’ executive team.
D2 Solutions will showcase the ProModRx integration at the Asembia AXS26 Summit in Las Vegas from April 26 to April 30.
KEY QUOTES
“D2’s focus has always been responding to market demands and the needs of our partners by helping address gaps in market access, operational support and patient services. The integration of ProModRx expands our ability to deliver the services and infrastructure our industry—and their patients—are asking for. Together, we offer an ecosystem of solutions focused on helping patients start therapy faster and with fewer barriers.”
“This acquisition is an important step. It brings together the services and infrastructure our clients need to connect enrollment, reimbursement, fulfillment and ongoing engagement more effectively—ultimately creating a better experience for patients.”
Dean Erhardt, Founder and CEO, D2 Solutions
“D2 has been a respected name in this industry for nearly two decades. ProModRx’s technology and services are a natural fit for D2’s UltraTouch Engage and Verify offerings. Together, we can offer our shared clients a broader and deeper set of solutions that support enrollment, reimbursement, fulfillment and ongoing engagement all within a single, integrated model.”
Jerry Smith, General Manager, ProModRx
